Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize the FDA animal drug user fee programs and improve
the review of products regulated by FDA.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 1418 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII,
(1) the following hearing was used to develop or
consider H.R. 1418:
On March 30, 2023, the Subcommittee on
Health held a hearing on H.R. 1418. The Subcommittee
received testimony from:
Ms. Tracey Forfa, J.D.,
Director, Center for Veterinary Medicine (CVM),
U.S. Food and Drug Administration (FDA);
Ms. Rachel Cumberbatch, DVM,
Director, Regulatory Affairs, Animal Drugs,
Animal Health Institute (AHI);
Ms. Stephanie Batliner, Chair,
Generic Animal Drug Alliance (GADA); and
Ms. Lori Teller, DVM, President,
American Veterinary Medical Association (AVMA).
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 1418 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
TITLE I: FEES RELATING TO ANIMAL DRUGS
Section 1. Short title
Section 1 provides a short title for the legislation, the
``Animal Drug and Animal Generic User Fee Amendments of 2023.''
Section 2. Table of contents
Section 2 provides a table of contents for the legislation.
TITLE I: FEES RELATING TO ANIMAL DRUGS
Section 101. Short title; finding
Section 101 establishes a short title for Title I, the
``Animal Dug User Fee Amendments of 2023.'' It also dedicates
fees authorized by this title toward expediting the animal drug
development process and review of animal drug applications as
set forth by statute.
Section 102. Definitions
Section 102 adds to the definition of ``process for the
review of abbreviated applications for new animal drugs''
activities necessary to implement US-EU and US-UK mutual
recognition agreements, with respect to new animal drug
products subject to review.
Section 103. Authority to assess and use animal drug fees
Section 103 reauthorizes FDA's animal drug user fee program
through 2028 and updates the base revenue amount for ADUFA V.
It also provides for the negotiated resource levels and updated
fee-setting process.
Section 104. Reauthorization; reporting requirements
Section 104 reauthorizes FDA reporting requirements to
Congress relating to the agency's progress in implementing its
user fee authorities and in meeting performance goals, as set
forth in the commitment letter submitted to the Congressional
Record.
Section 105. Savings clause
Section 105 preserves authorities to assess fees pursuant
to part 4 of subchapter C of chapter VII of FFDCA, effective
until enactment of this title.
Section 106. Effective date
Section 106 provides that amendments made by this title
shall take effect October 1, 2023, or the date of enactment,
whichever is later.
Section 107. Sunset dates
Section 107 provides that reporting requirements and
authorities to collect and assess user fees for the process of
the review of new animal drugs shall cease to be effective
October 1, 2028.
TITLE II: FEES RELATING TO GENERIC ANIMAL DRUGS
Section 201. Short title; finding
Section 201 establishes a short title for Title II,
``Animal Generic Drug User Fee Amendments of 2023.'' It also
dedicates fees authorized by this title toward expediting the
generic new animal drug development process and review of
abbreviated applications for generic new animal drug
applications as set forth by statute.
Section 202. Authority to assess and use generic new animal drug fees
Section 202 reauthorizes FDA's generic animal drug user fee
program through 2028 and updates the base revenue amount for
AGDUFA IV. It establishes a new fee type for generic
investigational new animal drug files and provides for
negotiated resource levels. It also adds to the definition of
``process for the review of abbreviated applications for
generic new animal drugs'' activities necessary to implement
US-EU and US-UK mutual recognition agreements with respect to
generic new animal drug products subject to review.
Section 203. Reauthorization; reporting requirements
Section 203 reauthorizes FDA reporting requirements to
Congress relating to the agency's progress in implementing its
user fee authorities and in meeting performance goals, as set
forth in the commitment letter submitted to the Congressional
Record.
Section 204. Savings clause
Section 204 preserves authorities to assess fees pursuant
to part 5 of subchapter C of chapter VII of FFDCA, effective
until enactment of this title.
Section 205. Effective date
Section 205 provides that amendments made by this title
shall take effect October 1, 2023, or the date of enactment,
whichever is later.
Section 206. Sunset dates
Section 206 provides that reporting requirements and
authorities to assess user fees for the process of the review
of generic new animal drugs shall cease to be effective October
1, 2028.
TITLE III: SUPPORTING ANIMAL AND HUMAN HEALTH
Section 301. Reporting requirements
Section 301 updates requirements for FDA reporting to
Congress to include data regarding the review process for
animal drug applications and sponsor requests for in-person,
face-to-face meetings in FY2024 and FY2025.
Section 302. Major species
Section 302 amends the definition of ``major species'' in
the Federal Food, Drug, and Cosmetic Act to allow for the
Secretary, through rulemaking, to add or remove species from
the definition.
Section 303. Antimicrobial resistance
Section 303 requires FDA, not later than December 31, 2023,
to submit to Congress a report describing activities conducted
by FDA's Center for Veterinary Medicine (CVM) during FY2019
through FY2023 to support antimicrobial stewardship in
veterinary settings. FDA must also report its goals to support
antimicrobial stewardship in veterinary settings, activities it
plans to execute in FY2024 through FY2028 to support those
goals, and metrics it plans to use to evaluate progress toward
those goals. Section 303 also requires FDA to submit, not later
than 120 days after the end of each fiscal year in which animal
drug user fees are collected, annual progress reports regarding
antimicrobial stewardship and activities undertaken to
incentivize the development of new animal antimicrobials.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
FEDERAL FOOD, DRUG, AND COSMETIC ACT
* * * * * * *
CHAPTER II--DEFINITIONS
Sec. 201. For the purposes of this Act--
(a)(1) The term ``State'', except as used in the last
sentence of section 702(a), means any State or Territory of the
United States, the District of Columbia, and the Commonwealth
of Puerto Rico.
(2) The term ``Territory'' means any Territory or possession
of the United States, including the District of Columbia, and
excluding the Commonwealth of Puerto Rico and the Canal Zone.
(b) The term ``interstate commerce'' means (1) commerce
between any State or Territory and any place outside thereof,
and (2) commerce within the District of Columbia or within any
other Territory not organized with a legislative body.
(c) The term ``Department'' means the Department of Health
and Human Services.
(d) The term ``Secretary'' means the Secretary of Health and
Human Services.
(e) The term ``person'' includes individual, partnership,
corporation, and association.
(f) The term ``food'' means (1) articles used for food or
drink for man or other animals, (2) chewing gum, and (3)
articles used for components of any such article.
(g)(1) The term ``drug'' means (A) articles recognized in the
official United States Pharmacopeia, official Homeopathic
Pharmacopeia of the United States, or official National
Formulary, or any supplement to any of them; and (B) articles
intended for use in the diagnosis, cure, mitigation, treatment,
or prevention of disease in man or other animals; and (C)
articles (other than food) intended to affect the structure or
any function of the body of man or other animals; and (D)
articles intended for use as a component of any articles
specified in clause (A), (B), or (C). A food or dietary
supplement for which a claim, subject to sections 403(r)(1)(B)
and 403(r)(3) or sections 403(r)(1)(B) and 403(r)(5)(D), is
made in accordance with the requirements of section 403(r) is
not a drug solely because the label or the labeling contains
such a claim. A food, dietary ingredient, or dietary supplement
for which a truthful and not misleading statement is made in
accordance with section 403(r)(6) is not a drug under clause
(C) solely because the label or the labeling contains such a
statement.
(2) The term ``counterfeit drug'' means a drug which, or the
container or labeling of which, without authorization, bears
the trademark, trade name, or other identifying mark, imprint,
or device, or any likeness thereof, of a drug manufacturer,
processor, packer, or distributor other than the person or
persons who in fact manufactured, processed, packed, or
distributed such drug and which thereby falsely purports or is
represented to be the product of, or to have been packed or
distributed by, such other drug manufacturer, processor,
packer, or distributor.
(h)(1) The term ``device'' (except when used in paragraph (n)
of this section and in sections 301(i), 403(f), 502(c), and
602(c)) means an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or
related article, including any component, part, or accessory,
which is--
(A) recognized in the official National Formulary, or the
United States Pharmacopeia, or any supplement to them,
(B) intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals, or
(C) intended to affect the structure or any function of the
body of man or other animals, and
which does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals
and which is not dependent upon being metabolized for the
achievement of its primary intended purposes. The term
``device'' does not include software functions excluded
pursuant to section 520(o).
(2) The term ``counterfeit device'' means a device which, or
the container, packaging, or labeling of which, without
authorization, bears a trademark, trade name, or other
identifying mark or imprint, or any likeness thereof, or is
manufactured using a design, of a device manufacturer,
processor, packer, or distributor other than the person or
persons who in fact manufactured, processed, packed, or
distributed such device and which thereby falsely purports or
is represented to be the product of, or to have been packed or
distributed by, such other device manufacturer, processor,
packer, or distributor.
(i) The term ``cosmetic'' means (1) articles intended to be
rubbed, poured, sprinkled, or sprayed on, introduced into, or
otherwise applied to the human body or any part thereof for
cleansing, beautifying, promoting attractiveness, or altering
the appearance, and (2) articles intended for use as a
component of any such articles; except that such term shall not
include soap.
(j) The term ``official compendium'' means the official
United States Pharmacopeia, official Homeopathic Pharmacopeia
of the United States, official National Formulary, or any
supplement to any of them.
(k) The term ``label'' means a display of written, printed,
or graphic matter upon the immediate container of any article;
and a requirement made by or under authority of this Act that
any word, statement, or other information appear on the label
shall not be considered to be complied with unless such word,
statement, or other information also appears on the outside
container or wrapper, if any there be, of the retail package of
such article, or is easily legible through the outside
container or wrapper.
(l) The term ``immediate container'' does not include package
liners.
(m) The term ``labeling'' means all labels and other written,
printed, or graphic matter (1) upon any article or any of its
containers or wrappers, or (2) accompanying such article.
(n) If an article is alleged to be misbranded because the
labeling or advertising is misleading, then in determining
whether the labeling or advertising is misleading there shall
be taken into account (among other things) not only
representations made or suggested by statement, word, design,
device, or any combination thereof, but also the extent to
which the labeling or advertising fails to reveal facts
material in the light of such representations or material with
respect to consequences which may result from the use of the
article to which the labeling or advertising relates under the
conditions of use prescribed in the labeling or advertising
thereof or under such conditions of use as are customary or
usual.
(o) The representation of a drug, in its labeling, as an
antiseptic shall be considered to be a representation that it
is a germicide, except in the case of a drug purporting to be,
or represented as, an antiseptic for inhibitory use as a wet
dressing, ointment, dusting powder, or such other use as
involves prolonged contact with the body.
(p) The term ``new drug'' means--
(1) Any drug (except a new animal drug or an animal
feed bearing or containing a new animal drug) the
composition of which is such that such drug is not
generally recognized, among experts qualified by
scientific training and experience to evaluate the
safety and effectiveness of drugs, as safe and
effective for use under the conditions prescribed,
recommended, or suggested in the labeling thereof,
except that such a drug not so recognized shall not be
deemed to be a ``new drug'' if at any time prior to the
enactment of this Act it was subject to the Food and
Drugs Act of June 30, 1906, as amended, and if at such
time its labeling contained the same representations
concerning the conditions of its use; or
(2) Any drug (except a new animal drug or an animal
feed bearing or containing a new animal drug) the
composition of which is such that such drug, as a
result of investigations to determine its safety and
effectiveness for use under such conditions, has become
so recognized, but which has not, otherwise than in
such investigations, been used to a material extent or
for a material time under such conditions.
(q)(1)(A) Except as provided in clause (B), the term
``pesticide chemical'' means any substance that is a pesticide
within the meaning of the Federal Insecticide, Fungicide, and
Rodenticide Act, including all active and inert ingredients of
such pesticide. Notwithstanding any other provision of law, the
term ``pesticide'' within such meaning includes ethylene oxide
and propylene oxide when such substances are applied on food.
(B) In the case of the use, with respect to food, of a
substance described in clause (A) to prevent, destroy, repel,
or mitigate microorganisms (including bacteria, viruses, fungi,
protozoa, algae, and slime), the following applies for purposes
of clause (A):
(i) The definition in such clause for the term
``pesticide chemical'' does not include the substance
if the substance is applied for such use on food, or
the substance is included for such use in water that
comes into contact with the food, in the preparing,
packing, or holding of the food for commercial
purposes. The substance is not excluded under this
subclause from such definition if the substance is
ethylene oxide or propylene oxide, and is applied for
such use on food. The substance is not so excluded if
the substance is applied for such use on a raw
agricultural commodity, or the substance is included
for such use in water that comes into contact with the
commodity, as follows:
(I) The substance is applied in the field.
(II) The substance is applied at a treatment
facility where raw agricultural commodities are
the only food treated, and the treatment is in
a manner that does not change the status of the
food as a raw agricultural commodity (including
treatment through washing, waxing, fumigating,
and packing such commodities in such manner).
(III) The substance is applied during the
transportation of such commodity between the
field and such a treatment facility.
(ii) The definition in such clause for the term